The global demand for Contract Manufacturing Organizations (CDMO) is expected to benefit from the outbreak of the Coronavirus pandemic. The contract manufacturing company segment is anticipated to open up lucrative business growth opportunities. The global CMO market is expected to hit US$241.3 billion in 2024, with a compound annual growth rate (CAGR) of 9.80 percent from 2020 to 2024.
The contract manufacturing sector in Europe is nearing potential, with expansion plans aplenty. Boehringer opened the first phase of the US$ 77 million facilities which includes a single-use bioreactor that can handle up to 2000 liters of clinical supplies or industrial output. Also, Rentschler, which is looking to expand internationally, added a new facility to its Laupheim, Germany, location two years ago to increase capacity.
In Europe's biopharmaceutical contract manufacturing industry, the biologics segment had the largest market share in 2020. The contract manufacturing of biologics has seen a big uptick. This is due to difficulties in producing large-scale biologics on a small scale in-house. Sanofi, for example, has hired Boehringer Ingelheim to produce its biologics pipeline. Many organizations are turning to CMOs to expedite the development process and reduce production costs. These markets demonstrate and witness growth at a significant rate in Europe region.
ABOUT CHIME BIOLOGICS
Chime Biologics, a China-based, world-class Contract Development and Manufacturing Organization (CDMO), providing customer-centric and cost-effective services for timely premier-quality biopharmaceutical development and manufacturing. We provide one stop comprehensive solution supporting our customers from early-stage biopharmaceutical development through late-stage clinical and commercial manufacturing, catering to the evolving needs of the dynamic biopharmaceutical industry. We pledge to make world-class biopharmaceuticals affordable and accessible to all patients globally through manufacturing innovation, and empowering therapeutic advancement for improvement of human health.
With our State-of-the-art facility and in-house world class expert team, we are committed for excellence upholding highest degree of integrity. We are ISO 14001:2015 and ISO 45001:2018 certified. Our World’s first GE KuBio facility is located at Wuhan’s BioLake biotech industry development zone of China, with clear path to expand the total capacity up to 140,000+ in the near future.
Phone:+86 27 8787 9208
Asahi Kasei Bioprocess is the established global market leader in virus filtration products, with its Planova virus removal filters having an unrivalled 30 years history of trusted use in the production of biotherapeutics, such as biopharmaceuticals and plasma derived drug products.
For more info, please check: www.ak-bio.com
Pall Corporation provides critical filtration, separation, and purification solutions to meet the demanding needs of a broad spectrum of life sciences and industrial customers around the globe. Across 80 locations and 10,000 people worldwide, we are unified by a singular drive: to solve our customers' biggest fluid management challenges. And in doing so advance health, safety, and environmentally responsible technologies. Together, our Life Sciences and Industrial teams serve a diverse range of customers including biotechnology, pharmaceutical, medical, food and beverage, laboratory, microelectronics, aerospace, fuels, petrochemical, chemical, automotive and power generation industries. Our industry-leading technologies and solutions are at work in countless applications, protecting critical operating assets, improving product quality, safeguarding the health, and minimizing emissions and waste
For more info, please check: https://www.pall.com/en/biotech.html
Abzena is a leading contract provider of integrated discovery, development and manufacturing services for biologics and antibody drug conjugates (ADCs). Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information, please see www.abzena.com.
Catalent Biologics has 20+ years’ experience in development, manufacturing, and analytical services for new biological entities, gene therapies, biosimilars, and antibody-drug conjugates. Catalent Biologics has worked with 600+ mAbs and 80+ proteins, with 12 marketed products using GPEx® cell line engineering technology, 25+ commercially-approved products through fill/finish and 40+ active clinical and commercial gene therapy programs.
With tailored solutions for clinical through commercial supply, Catalent Biologics brings better biologic treatments to patients, faster.
- Catalent Biologics’ capabilities include:
- GPEx® technology
- SMARTag® bioconjugation technology
- Industry-leading expertise in AAV vectors, next-generation vaccines and oncolytic virus production
- State-of-the-art biomanufacturing facilities
- Stand-alone and integrated analytical services
- Award-winning fill/finish facilities
For more information, please visit: https://biologics.catalent.com/
Present your expertise to the Asian Bioprocessing industry’s key stakeholders through a variety of available speaking packages.
Join the exhibition, and build an impressive presence among your potential clients.
Emphasize on your messages by promoting your brand alongside exhibition and thought leadership.
Engage with and build lasting connections that matter the most to your business.
Gain exclusive access to contacts of high-profile attendees through intimate networking opportunities.